论文信息 - Collateral damage: benchmarking off-target effects in genome editing - 字舞流文

Collateral damage: benchmarking off-target effects in genome editing

This editorial discusses what levels of off-target effects can be tolerated in genome editing, in the context of various types of applications.

[1] Martha L. Bulyk,et al. Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch , 2018, Cell.

[2] F. Urnov,et al. A call for science-based review of the European court's decision on gene-edited crops , 2018, Nature Biotechnology.

[3] Charles D. Yeh,et al. Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq , 2018, Science.

[4] Dana Carroll,et al. Genome engineering with targetable nucleases. , 2014, Annual review of biochemistry.

[5] J. Doudna,et al. The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[6] Aaron R Cooper,et al. CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[7] David Cyranoski,et al. The CRISPR-baby scandal: what’s next for human gene-editing , 2019, Nature.

[8] Shengdar Q Tsai,et al. Illuminating the genome-wide activity of genome editors for safe and effective therapeutics , 2018, Genome Biology.

[9] David A. Williams,et al. Concise Review: Lessons Learned From Clinical Trials of Gene Therapy in Monogenic Immunodeficiency Diseases , 2014, Stem cells translational medicine.

[10] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..